Robert P. Bowser, Ph.D.

Dr. Bowser is presently Professor of Neurology and Neurobiology at the Barrow Neurological Institute and Adj. Prof. at the University of Pittsburgh. He co-founded Knopp Biosciences in 2004, and was the founder of Iron Horse Diagnostics in 2012. He is a world expert in ALS research, including the potential use of biomarkers as diagnostic indicators of disease.


Merit E. Cudkowicz, M.D., M.Sc.

Dr. Cudkowicz is the Julieanne Dorn Professor of Neurology at Harvard Medical School and Co-Chair of the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS, www.nealsconsortium.org) . She has tested several therapies in human clinical trials for the treatment of ALS and has expertise in trial design and conduct.


Terry Heiman-Patterson, M.D.

Dr. Heiman-Patterson is Section Chief of Neuromuscular Disorders at Drexel University College of Medicine. She is also Medical Director of the MDA/ALS Center of Hope at Drexel, and Co-Founder of the ALS Hope Foundation.


May Khanna, Ph.D.

Dr. Khanna has worked in the areas of RNA, RNA-protein, and protein-protein interactions for over 20 years. In her laboratory at the University of Arizona (Department of Pharmacology), she uses multiple biophysical tools including Surface Plasmon Resonance (SPR), Nuclear Magnetic Resonance (NMR) and X-ray crystallography to define protein-protein, protein-RNA and protein-small molecule interactions towards the development of novel therapeutics. Although her initial experience involved the development of small molecule inhibitors of protein-protein interactions and enzymes using structure-based computational in silico studies as well as high throughput screens towards the discovery of anti-cancer drugs, her laboratory now focuses on neurodegenerative targets. She is a co-inventor for compounds that are pre-clinical leads in ALS and for pain therapeutics through a company set-up at the University of Arizona (Regulonix).